In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses ...

"The results of this phase 2 trial establish the potential for ziftomenib to induce responses and prolong life in responding patients with relapsed or refractory acute myeloid leukemia characterized ...

Kura Oncology and Kyowa Kirin announced promising results from the KOMET-007 trial, which evaluated ziftomenib, an oral investigational menin inhibitor, in combination with standard chemotherapy for ...

Ziftomenib is approved for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, offering a new targeted treatment option. The approval is based on the KOMET-001 trial, which showed ...

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...

KOMZIFTI™ (ziftomenib) is approved by the U.S. Food and Drug Administration (FDA) as monotherapy for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation who have no ...

Kura Oncology, Inc. remains a Buy, driven by ziftomenib's launch and promising combination trial data in AML. Ziftomenib's initial single-agent results are modest, but combination regimens (notably ...

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML. The frontline cohort enrolled 99 patients, including 49 with NPM1 ...

Good day, everyone. My name is Stefan, and I'll be your conference operator today. At this time, I'd like to welcome you to Kura Oncology's investor call to discuss the long-term results of ziftomenib ...

Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies. γ9δ2 T-cell activation ...

KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...